Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bornamin plus silver sulfadiazine for diabetic foot ulcers
IRCT20241027063508N1Phase 3Completed
- Sponsor
- Borna Biopharma
- Start
- Dec 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Bornamin, silver sulfadiazine and epidermal growth factor in diabetic foot ulcer (DFU) (2 arms), sponsored by Borna Biopharma. Primary endpoints: Granulation tissue and wound characteristics, Wound involvement area and 1 more. Started Dec 2024; status: completed.
02
Drugs
Bornaminsilver sulfadiazineepidermal growth factor
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on IRCT20241027063508N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241027063508N1.